Scholar Rock Holding Corp (SRRK) stock
SRRKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$48.00+2.92 (+6.48%)
Close on Nov 18, 2026Market cap $5.85BP/E –Yield –
Scholar Rock operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Scholar Rock's operating income for the twelve months ending Jun 30, 2026 was -$406.36M. For fiscal 2025 it was -$384.65M. The highest annual figure on record is -$25.03M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$384.65M | – |
| FY2024 | Dec 31, 2024 | -$252.05M | – |
| FY2023 | Dec 31, 2023 | -$171.30M | – |
| FY2022 | Dec 31, 2022 | -$134.37M | – |
| FY2021 | Dec 31, 2021 | -$129.92M | – |
| FY2020 | Dec 31, 2020 | -$86.88M | – |
| FY2019 | Dec 31, 2019 | -$54.54M | – |
| FY2018 | Dec 31, 2018 | -$50.69M | – |
| FY2017 | Dec 31, 2017 | -$25.03M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$108.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$102.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$91.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$103.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$112.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$77.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$69.36M | – |
| Q3 FY2024 | Sep 30, 2024 | -$64.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$59.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$58.42M | – |
| Q4 FY2023 | Dec 31, 2023 | -$48.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$43.67M | – |
| Q2 FY2023 | Jun 30, 2023 | -$39.08M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.51M | – |
| Q4 FY2022 | Dec 31, 2022 | -$40.43M | – |
| Q3 FY2022 | Sep 30, 2022 | -$43.86M | – |
| Q2 FY2022 | Jun 30, 2022 | -$43.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.93M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.36M | – |
| Q3 FY2021 | Sep 30, 2021 | -$37.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.27M | – |
| Q1 FY2021 | Mar 31, 2021 | -$27.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$26.10M | – |
| Q3 FY2020 | Sep 30, 2020 | -$23.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.46M | – |
| Q1 FY2020 | Mar 31, 2020 | -$17.69M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.35M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.11M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.39M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.70M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.56M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$14.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.02M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.46M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.94M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.89M | – |
See a number that looks wrong?